AIRG vs AVGO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AIRG exhibits severe financial distress signals, with a Piotroski F-Score of 1/9 indicating extreme weakness in operational and financial health. The company is unprofitable across all margins, with a negative ROE of -21.69% and a revenue decline of 19.6% YoY, while insider selling activity totals $0.18M over six months. Although the debt/equity ratio is low at 0.17 and current ratio is healthy at 1.98, the absence of an Altman Z-Score and persistent losses raise significant solvency concerns. The stock trades at a forward P/E of 13.63, but this is misleading given the negative earnings and lack of sustainable profitability. Analysts rate it 'strong_buy' with a target of $6.12, but this appears disconnected from fundamental reality.
Broadcom exhibits a dichotomy between elite operational performance and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health, the stock trades at a massive premium to its Graham Number ($44.08) and Intrinsic Value ($151.04). This valuation gap is partially justified by a very attractive PEG ratio (0.68) and strong forward P/E (19.65), suggesting high growth expectations. However, aggressive insider selling by the CEO and CFO, combined with a bearish technical trend, offsets the strong analyst 'strong_buy' consensus.
Compare Another Pair
Related Comparisons
AIRG vs AVGO: Head-to-Head Comparison
This page compares Airgain, Inc. (AIRG) and Broadcom Inc. (AVGO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.